Genzyme’s Multiple Sclerosis Franchise Featured at ECTRIMS

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY) announced today that new data from its Aubagio (teriflunomide) and Lemtrada (alemtuzumab) clinical development programs will be presented during the 29th Congress of the European Committee for Research and Treatment in Multiple Sclerosis (ECTRIMS) and the 18th Annual Conference of Rehabilitation in MS (RIMS) to be held in Copenhagen, Denmark, October 2-5.

The Challenges of Disease Management in MS: Navigating the Changing Landscape

The recent European Commission approvals of Aubagio and Lemtrada make this years ECTRIMS particularly significant for Genzymes MS Franchise, said Genzyme CEO and President David Meeker. As we prepare to launch both products, we look forward to presenting these new data, which highlight the unique potential of our products to treat a broad spectrum of relapsing remitting MS patients and reflect our strong commitment to the MS community.

Presentations at ECTRIMS/RIMS featuring Aubagio and Lemtrada are as follows.

Aubagio:

Oral Platform Presentation

Poster Presentations

Lemtrada:

Poster Presentations

Abstracts are available on the ECTRIMS/RIMS website.

Read the original:
Genzyme’s Multiple Sclerosis Franchise Featured at ECTRIMS